Outpatient Management of COVID-19: A Primer for the Dermatologist

PURPOSE OF REVIEW: To summarize diagnostic and therapeutic management of COVID-19 in the outpatient setting for dermatologists. RECENT FINDINGS: Paxlovid (nirmatrelvir-ritonavir) is the preferred treatment in patients with mild symptoms at high risk of progression to severe SARS-CoV2 infection. Addi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Sonia, Gelfand, Joel M., Calabrese, Cassandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Covid-19 in Dermatology (J. M. Gelfand, Section editor)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9391204/
https://www.ncbi.nlm.nih.gov/pubmed/36035078
http://dx.doi.org/10.1007/s13671-022-00368-3
Descripción
Sumario:PURPOSE OF REVIEW: To summarize diagnostic and therapeutic management of COVID-19 in the outpatient setting for dermatologists. RECENT FINDINGS: Paxlovid (nirmatrelvir-ritonavir) is the preferred treatment in patients with mild symptoms at high risk of progression to severe SARS-CoV2 infection. Additional options include monoclonal antibodies (bebtelovimab), remdesivir, and molnupiravir. SUMMARY: Dermatologists need to be aware of recent developments in diagnostic and therapeutic management of COVID-19 in the outpatient setting, as their patients may rely on dermatologists to provide advice, particularly in cases where treatments for dermatological disease may impact the risk of COVID-19 and/or vaccine efficacy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13671-022-00368-3.

Ejemplares similares